The Interconnection Between Pharmaceutical Development and Preclinical Research (Review)
https://doi.org/10.33380/2305-2066-2023-12-2-155-163
Abstract
Introduction. Pharmaceutical development of an innovative highly effective and competitive drug is a long and expensive process, the result of which is quite difficult to predict in advance. To speed up the entry of a new drug to the treatment and reduce the developer's material costs, it is advisable to include preclinical experiments in the process of creating a drug.
Text. The purpose of this work is to create a justified approach to the implementation of laboratory pharmaceutical development involving in vivo studies. The inclusion of preclinical studies in the process of laboratory pharmaceutical development will eliminate the negative impact of pharmaceutical factors on the bioavailability of a drugs and avoid errors in the selection of excipients, as well as reduce material and time costs. The review presents examples that demonstrate the relevance of conducting preclinical experiments at different stages of pharmaceutical development. These examples made it possible to describe a clearer algorithm of actions in the laboratory pharmaceutical development of a new drug from the moment a drug candidate molecule is selected.
Conclusion. Due to increase the probability of successful pharmaceutical development at initial stage, it is necessary to carry out pharmacokinetic and/or pharmacodynamic experiments to make it possible to develop a drug with an optimal pharmacokinetic profile, reduce the number of preclinical studies, the cost of development, and ensure successful translation of data into clinical practice.
About the Authors
I. N. Ampilogova
JSC "RMC "HOUSE OF PHARMACY"
Russian Federation
Russian Federation
3/245, Zavodskaya str., Kuzmolovsky, Vsevolozhski district, Leningrad region, 188663
M. V. Karlina
JSC "RMC "HOUSE OF PHARMACY"
Russian Federation
Russian Federation
3/245, Zavodskaya str., Kuzmolovsky, Vsevolozhski district, Leningrad region, 188663
V. G. Makarov
JSC "RMC "HOUSE OF PHARMACY"
Russian Federation
Russian Federation
3/245, Zavodskaya str., Kuzmolovsky, Vsevolozhski district, Leningrad region, 188663
M. N. Makarova
JSC "RMC "HOUSE OF PHARMACY"
Russian Federation
Russian Federation
3/245, Zavodskaya str., Kuzmolovsky, Vsevolozhski district, Leningrad region, 188663
References
1. Basevich A. V., Dzjuba A. S., Kauhova I. E., Andreeva P. I. Creating new drugs design patterns. Step one. Pharmaceutical development. Pharmacy Formulas. 2019;1(1):22–31. (In Russ.) DOI: 10.17816/phf18519.
2. Miroshnichenko I. I., Kravtsova O. Y. Organizing of pharmacokinetic investigations. Pharmacokinetics and pharmacodynamics. 2021;(3):12–19. (In Russ.) DOI: 10.37489/2587-7836-2021-3-12-19.
3. Zherdev V. P., Bojko S. S., Shevchenko R. V., Gudasheva T. A. The role of pharmacokinetic and biopharmaceutical investigations in the creation of a new dipeptide drugs (experimental investigation). Pharmacokinetics and pharmacodynamics. 2017;1:3–10. (In Russ.)
4. Belov M. V., Shahmuradjan V. A. Improvement of a pharmaceutical enterprise’s business processes at the stage of preclinical development of new drugs. Business informatics. 2019;13:17–27. (In Russ.) DOI: 10.17323/1998-0663.2019.4.17.27.
5. Setkina S. B., Hishova O. M. Biopharmaceutical aspects drug technology and ways to modify bioavailability. Vestnik VGMU. 2014;13(4):162–172. (In Russ.)
6. Khan A. D., Singh L. Various techniques of bioavailability enhancement: a review. Journal of drug delivery and therapeutics. 2016;6(3):34–41. DOI: 10.22270/jddt.v6i3.1228.
7. Gupta R. J., Nagar V., Ansari J., Sharma A., Sarkar K., Mohd A. K. Bioavailability enhancement techniques for poorly soluble drugs: a review. Asian journal of pharmaceutical research and development. 2020;8:75-78. DOI:0.22270/ajprd.v8i2.664.
8. Samylina I. A., Tencova A. I., Rudakova I. P., Il’ina I. G., Skachilova S. Ja., Shilova E. V. Biopharmaceutical aspects of pharmacopoeial substances. Pharmacy. 2012;8:29–32. (In Russ.)
9. Kovaleva E. L., Bagirova V. L., Shanazarov K. S. Developing methodological approaches to standardization of pharmaceuticals. Pharmaceutical Chemistry Journal. 2010;4(1):35–42. (In Russ.)
10. Bansal K., Pankaj P., Rao P. R. T., Sathapathy K. P. A., Kochhar P. S. Micronization and dissolution enhancement of norethindrone. International journal of research in pharmacy and chemistry. 2011;1(3):315–319.
11. Kovaleva Ju. S., Zjablickaja N. K. Micronization of corticosteroid drugs and their use in medicine. Jeffektivnaja farmakoterapija. 2020;16(27):16–20. (In Russ.)
12. Date A. A., Halpert G., Babu T., Ortiz J., Kanvinde P., Dimitrion P., Narayan J., Zierden H., Betageri K., Musmanno O., Wiegand H., Huang X., Gumber S., Hanes J., Ensign L. M. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018;185:97–105. DOI: 10.1016/j.biomaterials.2018.09.005.
13. Sabroso C., Moreno-Ortega A., Blanco A. J., Sánchez A. F., Cano-Abad M., Torres-Suarez A. Overcoming glucocorticoid resistances and improving antitumor therapies: lipid and polymers carriers. Pharmaceutical research. 2015;32:968–985. DOI: 10.1007/s11095-014-1510-4.
14. Kolik L. G., Zherdev V. P., Bojko S. S., Konstantinopol’skij M. A., Raskin S. Ju., Gudasheva T. A., Mart’janov V. A., Seredenin S. B. Experimental pharmacokinetics and pharmacodynamics of the substance of the dipeptide anxiolytic GB-115. Jeksperimental’naja i klinicheskaja farmakologija. 2016;11:42–46. (In Russ.)
15. Cyrino F. Z., Bottino D. A., Lerond L., Bouskela E. Micronization enhances the protective effect of purified flavonoid fraction against postischaemic microvascular injury in the hamster cheek pouch. Clinical and experimental pharmacology and physiology. 2004;31:159–162. DOI: 10.1111/j.1440-1681.2004.03974.x.
16. Ivannikova E. V., Zherdev V. P., Bojko S. S., Blynskaja E. V., Turchinskaja K. G., Alekseev K. V. Study of pharmacokinetics and bioavailability in the creation of new original drugs with a peptide structure and their optimal dosage forms. Pharmacokinetics and Pharmacodynamics. 2013;2:1–17. (In Russ.)
17. Demchenko D. V., Dzhajn (Korsakova) E. A., Balaban’jan V. Ju., Makarova M. N., Makarov V. G. Development and Biopharmaceutical Evaluation of Tablets Based on the Poorly Water-soluble Substance 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil. Drug development & registration. 2020;9(4):79-87. (In Russ.) DOI: 10.33380/2305-2066-2020-9-4-79-87.
18. Arregui J. R., Kovvasu S. P., Kunamaneni P., Betageri G V. Carvedilol solid dispersion for enhanced oral bioavailability using rat model. Journal of applied pharmaceutical science. 2019;9(12):042–050. DOI: 10.7324/JAPS.2019.91207.
19. Mohan A., Gundamaraju R. In vitro and in vivo evaluation of fastdissolving tablets containing solid dispersion of lamotrigine. International Journal of Pharmaceutical Investigation. 2015;5(1):57–64. DOI: 10.4103/2230-973X.147235.
20. Rudakova I. P., Ilyina I. G., Skachilova S. Ya., Melentieva T. A., Mikhalev O. V., Samylina I. A. The polymorphism and properties of drugs. Pharmacy. 2009;(8):42–44. (In Russ.)
21. Gil’deeva G. N. Polymorphism: the influence on the quality of drugs and actual methods of analysis. Good Clinical Practice. 2017;1:56–60. (In Russ.)
22. Zanolla D., Perissutti B., Passerini N., Chierotti M. R., Hasa D., Voinovich D., Gigli L., Demitri N., Geremia S., Keiser J., Vioglio P. C., Albertini B. A new soluble and bioactive polymorph of praziquantel. European Journal of Pharmaceutics and Biopharmaceutics. 2018;127:19–28. DOI: 10.1016/j.ejpb.2018.01.018.
23. Du W., Zhou Y., Gong Y., Zhao C. Investigation of physicochemical properties and in-vitro in-vivo evaluation of agomelatine polymorphs. Asian journal of pharmaceutical sciences. 2013;8(3):181–190. DOI: 10.1016/j.ajps.2013.07.024.
24. Zhu X., Xu S., Lu L., Wang S., Zhao Q., Li D., Li J., Zhao H., Xu B. Preparation, characterization, and in vivo evaluation of a polymorphic form of valnemulin hydrogen tartrate. Journal of veterinary science. 2019;20(2):e16. DOI: 10.4142/jvs.2019.20.e16.
25. Aleeva G. N., Zhuravleva M. V., Khafiz’yanova R. K. The role of excipients in determining the pharmaceutical and therapeutic properties of medicinal agents (Review). Pharmaceutical chemistry journal. 2009;43(4):230–234. DOI: 10.1007/s11094-009-0265-4.
26. Koo O. M. Y. Excipients-Application challenges and examples of new excipients in advanced drug delivery systems. American pharmaceutical review. 2011;14(2):60–68.
27. Аlekseev K. V., Bueva V. V., Blynskaya E. V, Alekseev V. K., Adzyenko V. V. The role of excipients in solid dosage form during pharmaceutical development. East European Scientific Journal. 2019;9(49):48–52. (In Russ.)
28. Bochkov P. O., Shevchenko R. V., Litvin A. A., Kolyvanov G. B., Zherdev V. P. Factors, effecting on drug bioavailability. Pharmacokinetics and Pharmacodynamics. 2016;1:12–20. (In Russ.)
29. Vaithianathan S., Haidar S. H., Zhang X., Jiang W., Avon C., Dowling T. C., Shao C., Kane M., Hoag S. W., Flasar M. H., Ting T. Y., Polli J. E. Effect of common excipients on the oral drug absorption of biopharmaceutics classification system class 3 drugs cimetidine and acyclovir. Journal of pharmaceutical sciences. 2016;105:996–1005. DOI: 10.1002/jps.24643.
30. Fathima N., Tirunagari M., Qureshi H. K., Nandagopal A., Rao J. Drug-excipient interaction and its importance in dosage form development. Journal of applied pharmaceutical science. 2011;1:66–71.
31. Mai Y., Dou L., Madla C. M., Murdan S., Basit A. W. Sex-dependence in the effect of pharmaceutical excipients: polyoxyethylated solubilising excipients increase oral drug bioavailability in male but not female rats. Pharmaceutics. 2019;11(5):228. DOI: 10.3390/pharmaceutics11050228.
32. Koehl N. J., Henze L. J., Bennett-Lenane H., Faisal W., Price D. J., Holm R., Kuentz M., Griffin B. T. In silico, in vitro, and in vivo evaluation of precipitation inhibitors in supersaturated lipid-based formulations of venetoclax. Molecular pharmaceutics. 2021;18(6):2174–2188. DOI: 10.1021/acs.molpharmaceut.0c00645.
33. Fransén N., Morin M., Björk E., Edsman K. Physicochemical interactions between drugs and superdesintegrants. Journal of pharmacy and pharmacology. 2008;60:1583–1589. DOI: 10.1211/jpp.60.12.0003.
34. Yoo S. D., Lee S.-H., Kang E., Jun H., Jung J.-Y., Park J. W., Lee K.-H. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug development and industrial pharmacy. 2000;26(1):27–34. DOI: 10.1081/DDC-100100324.
35. Lee J.-H., Park C., Weon K.-Y., Kang C.-Y., Lee B.-J., Park J.-B. Improved Bioavailability of Poorly Water-Soluble Drug by Targeting Increased Absorption through Solubility Enhancement and Precipitation Inhibition. Pharmaceuticals. 2021;14:1255. DOI: 10.3390/ph14121255.
36. Joseph D., Renjitham S. S. The development and process optimization of atorvastatin calcium and Naringin bilayer tablet to improve the bioavailability of atorvastatin calcium by two-level factorial design using Design-Expert®. Journal of applied pharmaceutical science. 2020;1(6):070–077. DOI: 10.7324/japs.2021.110608.
Supplementary files
|
|
1. Графический абстракт | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(1MB)
|
Indexing metadata ▾ | |
Review
For citations:
Ampilogova I.N., Karlina M.V., Makarov V.G., Makarova M.N. The Interconnection Between Pharmaceutical Development and Preclinical Research (Review). Drug development & registration. 2023;12(2):155-163. (In Russ.) https://doi.org/10.33380/2305-2066-2023-12-2-155-163
Views:
5383
Email this article 